RxDoctor Payments DataLook up a doctor →

Ramalingam Ratnasabapathy, MD

Hematology & Oncology · Henderson, NVNPI 1144220781

Payments from drug & device makers

$161,335in general payments, 2019–2025

Across 791 payments — averaging $203.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$113K
  • Beone Medicines USA, Inc.$15K
  • Exelixis Inc.$9K
  • Incyte Corporation$3K
  • AstraZeneca$3K
  • Daiichi Sankyo Inc.$3K
  • plus $17K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.48$113,048
Beone Medicines USA, Inc.9$14,704
Exelixis Inc.20$8,883
Incyte Corporation23$2,784
AstraZeneca(2 entities)35$2,767
Daiichi Sankyo Inc.146$2,540
Genentech USA, Inc.22$2,344
Novartis88$2,329
Bayer10$1,187
Johnson & Johnson(2 entities)23$751
Gilead25$719
Merck28$690
Regeneron Healthcare Solutions, Inc.20$638
E.r. Squibb & Sons, L.L.C.12$607
Pfizer37$586
Astellas Pharma US Inc19$578
Sobi, Inc28$530
Jazz Pharmaceuticals Inc.5$491
Bristol Myers Squibb22$489
Tempus AI, Inc20$474
Karyopharm Therapeutics Inc.11$413
Azurity Pharmaceuticals, Inc.6$401
Lilly USA, LLC12$318
Ipsen Biopharmaceuticals, Inc14$284
Amgen13$258
Eisai Inc.11$228
AbbVie9$210
Sanofi7$178
EMD Serono, Inc.9$172
GSK6$145
Seagen Inc.3$145
Regeneron1$126
G1 Therapeutics, Inc.1$122
Genmab U.S., Inc.4$110
AVEO Pharmaceuticals, Inc.1$100
Stemline Therapeutics Inc.5$93
Mirati Therapeutics, Inc.3$77
Pharmacyclics LLC, An Abbvie Company3$74
Puma Biotechnology, Inc.4$74
Rigel Pharmaceuticals, Inc.3$70
Beigene USA, Inc.2$62
Secura Bio, Inc.1$56
Dendreon Pharmaceuticals LLC2$55
Geron Corporation2$48
Taiho Oncology, Inc.2$43
Blueprint Medicines Corporation2$43
Array Biopharma Inc2$30
Alnylam Pharmaceuticals Inc.1$28
Acrotech Biopharma Inc.1$27
Sun Pharmaceutical Industries Inc.1$27
Springworks Therapeutics, Inc.1$26
Servier Pharmaceuticals LLC1$24
Boehringer Ingelheim1$23
Recordati_rare_diseases_inc.1$22
Adaptive Biotechnologies Corporation1$21
Coherus Oncology, Inc.1$21
Sirtex Medical Inc1$20
Accord Healthcare, Inc.1$16
Foundation Medicine, Inc.1$13

How this compares

$161,335 in reported general payments places this provider in the 70th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada

Medicare billing

Part B allowed, 2024
$2,508,259
Medicare patients
407
Services billed
166,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →